SOPHiA GENETICS

SOPH

Market cap $322M

BOSTON , Nov. 11, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ on Complete Genomics' DNBSEQ-T1+ sequencing platform. The companies aim to broaden access to precision oncology testing by offering the best-in-class liquid biopsy and solid tumor applications to customers globally.

BOSTON and SAN DIEGO , Nov. 11, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and Element Biosciences, Inc., a biology company transforming the pace and accessibility of scientific discovery, today announced at the Association for Molecular Pathology (AMP) Annual Meeting a partnership that unites sequencing and AI analytics to streamline genomic workflows and accelerate the research supporting precision medicine. This collaboration integrates SOPHiA GENETICS' AI-powered analytics platform, SOPHiA DDM™, with Element's AVITI24™ 5D multiomic and AVITI™ sequencing systems to deliver a seamless, end-to-end workflow for next-generation sequencing (NGS).

SOPHiA GENETICS SA ( SOPH ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Kellen Sanger - Head of Strategy and Investor Relations Jurgi Camblong - Co-Founder, CEO & Director Ross Muken - President George Cardoza - Executive VP & CFO Conference Call Participants William Bonello - Craig-Hallum Capital Group LLC, Research Division Subhalaxmi Nambi - Guggenheim Securities, LLC, Research Division Mark Massaro - BTIG, LLC, Research Division Kyle Boucher - TD Cowen, Research Division Presentation Operator Good morning. My name is Kelsey, and I'll be your conference operator today.

BOSTON and ROLLE, Switzerland , Nov. 4, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September 30, 2025. Third Quarter  2025 Financial Results Revenue was $19.5 million, up 23% year-over-year Gross margin was 66.3% on a reported basis and 73.1% on an adjusted basis, compared to 67.2% reported and 73.1% adjusted in the prior year period Net IFRS loss was $20.0 million, up 9% year-over-year; Adjusted EBITDA loss was $10.2 million, up 8% year-over-year; Excluding the impact of elevated Swiss social charges on equity-based compensation following share price appreciation, adjusted EBITDA loss would have been $8.8 million, representing a 13% year-over-year improvement 2025 Financial Outlook Full year revenue is now expected to be in the range of $75 to $77 million, representing year-over-year growth of 15% to 18%.

BOSTON and ROLLE, Switzerland , Oct. 21, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today announced it will release its financial results for the third quarter 2025 before U.S. markets open on Tuesday, November 4, 2025. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m.

ROLLE, Switzerland and TOKYO , Oct. 16, 2025 /PRNewswire/ -- A.D.A.M. Innovations, Japan's leading private genetic testing company, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company pioneering data-driven medicine, today announced at ESMO a strategic agreement to bring cutting-edge liquid biopsy genomic testing to the Japanese population.

BOSTON and ROLLE, Switzerland , Oct. 16, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in AI-driven precision medicine, today announced the launch of SOPHiA DDM™ Digital Twins, a breakthrough research technology that creates dynamic, virtual representations of individual patients to simulate potential outcomes and help oncologists make better treatment decisions.   SOPHiA DDM™ Digital Twins uses each patient's unique clinical, biological, imaging, and genomic data to generate a computational replica of the patient and their individual disease.

SALT LAKE CITY and BOSTON , Sept. 23, 2025 /PRNewswire/ -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test.

SALT LAKE CITY and BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test.

BOSTON , Sept. 22, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the World CB & CDx Summit in Boston.